Amy Rudolph, PhD, Joins Thryv Therapeutics' Board
MONTREAL - Thryv Therapeutics Inc., a clinical-stage biotechnology company focusing on innovative serum glucocorticoid inducible kinase 1 (SGK1) inhibitors, announces that Amy Rudolph, PhD, is now a member of its Board of Directors. Dr. Rudolph brings over 25 years of significant experience from the pharmaceutical industry, with expertise in discovery, clinical development, medical affairs, and market access.
Experience and Contributions
Currently, Dr. Rudolph holds a pivotal role as the Head of Global Medical Affairs at Boehringer Ingelheim. She has been instrumental in leading a transformation aimed at developing a top-tier Medical Affairs organization that emphasizes external engagement, digital strategies, and advanced analytics.
“We are excited to have Amy Rudolph on our Board,” stated Paul Truex, Chairman and CEO of Thryv Therapeutics. “Her vast experience will be crucial as we advance our SGK1 inhibitor pipeline through to late-stage clinical trials.”
Dr. Rudolph expressed her enthusiasm by stating, “Joining Thryv Therapeutics' Board of Directors is an honor. The company's commitment to advancing science and focusing on patient needs speaks to me, and I am eager to aid in tackling significant cardiovascular issues.”
Prior Achievements
Before her tenure at Boehringer Ingelheim, Dr. Rudolph had leadership positions at Novartis, where she was Head of Healthcare Systems Partnerships and Global Drug Development. She also played key roles at Pfizer Inc., working on atherosclerosis and stroke projects, and contributed significantly to early drug development processes.
Throughout her illustrious career, Dr. Rudolph has been pivotal in the creation and launch of several heart-related therapies, including Eliquis, Inspra, and Entresto. Her contributions have not gone unnoticed, as she is credited as an inventor on 13 patents and has numerous scientific publications under her belt.
Thryv Therapeutics' Focus
Thryv Therapeutics is dedicated to addressing pressing cardiovascular conditions. Their SGK1 inhibitors are designed to combat various issues, including Long QT Syndrome, heart failure, and atrial fibrillation. The lead clinical candidate, THRV-1268, is seen as a potential breakthrough in the landscape of heart treatments.
As part of this transition, Scott Weiner will step down from his active role on the Board but will continue to provide guidance in an advisory position, remaining involved in the company’s subsidiary, Thryv Therapeutics USA, Inc.
About Thryv Therapeutics
Thryv Therapeutics Inc. is a biotech innovator based in Montreal, Quebec. The company focuses on developing targeted treatments for genetic channelopathies and cardiometabolic diseases with the help of their advanced SGK1 inhibitors. This approach aligns with their commitment to precision medicine, addressing the unmet needs in cardiovascular health.
Frequently Asked Questions
What is the role of Dr. Amy Rudolph at Thryv Therapeutics?
Dr. Rudolph has been appointed to the Board of Directors, bringing her extensive experience in the pharmaceutical industry to support the company's mission.
What are SGK1 inhibitors?
SGK1 inhibitors are a class of drugs targeted to address serious cardiovascular conditions by regulating mechanisms underlying cardiac functionality.
What is the significance of the THRV-1268 candidate?
THRV-1268 is noted for its potential to change treatment paradigms for serious heart conditions like heart failure and atrial fibrillation.
How is Thryv Therapeutics addressing cardiovascular diseases?
The company focuses on developing innovative therapies that specifically target genetic issues in the cardiovascular sector.
Who is Scott Weiner, and what is his new role?
Scott Weiner has previously served on the Board and is now transitioning to an advisory role while continuing his involvement with the company's subsidiary.
